专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

WO1997013855A1 MELANOMA-ASSOCIATED PROTEIN 审中-公开
标题翻译：梅毒相关蛋白
公开(公告)号：WO1997013855A1
公开(公告)日：1997-04-17
申请号：PCT/EP1995003988
申请日：1995-10-10
申请人： NOVARTIS AG , PLUSCHKE, Gerd , SCHMID, Peter
发明人： NOVARTIS AG
IPC分类号： C12N15/12
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/00 , C07K14/82 , C12N2799/021
摘要： This invention relates to a melanoma-associated protein (MCSP), a derivative of said protein and to means and methods for the production thereof. The invention is also directed to isolated nucleic acids coding for said melanoma-associated protein, to a method of obtaining such nucleic acid molecules, and to their expression. Furthermore, the invention is directed to uses of said protein and nucleic acid, particularly uses relating to diagnosis, prophylaxis and therapy of tumors producing the protein, such as human malignant melanoma, sarcoma and glioblastoma.
摘要翻译：本发明涉及黑素瘤相关蛋白（MCSP），所述蛋白质的衍生物及其制备方法和方法。本发明还涉及编码所述黑素瘤相关蛋白的分离的核酸，获得这种核酸分子的方法及其表达。此外，本发明涉及所述蛋白质和核酸的用途，特别是涉及产生蛋白质的肿瘤（例如人恶性黑素瘤，肉瘤和成胶质细胞瘤）的诊断，预防和治疗相关的应用。

52. 发明申请

WO1997011953A1 NOVEL HYDROXYLATED AND ALKOXYLATED N- AND/OR P-ARALKYLPHOSPHINIC ACID DERIVATIVES 审中-公开
标题翻译：新型羟基和烷氧基的N-和/或β-阿拉基磷酸衍生物
公开(公告)号：WO1997011953A1
公开(公告)日：1997-04-03
申请号：PCT/EP1996004062
申请日：1996-09-17
申请人： NOVARTIS AG , STAMPF, Philippe , FRÖSTL, Wolfgang , MICKEL, Stuart, John , ZIMMERMANN, Kaspar
发明人： NOVARTIS AG
IPC分类号： C07F09/30
CPC分类号： C07F9/306 , C07F9/301
摘要： Hydroxylated or alkoxylated N,P-aralkylphosphinic acid derivatives of formula (I) wherein R1 denotes an aliphatic, cycloaliphatic or aromatic group, R2 and R5 independently of each other, represent hydrogen or an aliphatic group, R3 denotes hydrogen or hydroxy and R4 denotes hydrogen or R3 and R4 together represent oxo, R6 denotes hydrogen or [ H]- or [ C]-labeled alkyl, R7 denotes hydrogen, lower alkyl, lower alkoxy, halogen, carboxy, carbamoyl or cyano, and wherein one of X1 and X2 represents a group of the formula >N- and the other represents a group of the formula >P(=O)(OH)-, and their salts are novel. Compounds of formula (I) wherein R6 denotes hydrogen, can be easily converted into the corresponding compounds of formula (I) in which R6 denotes [ H]- or [ C]-labeled alkyl, and optionally into pharmaceutically acceptable salts thereof which can be used as a tool for localization and assessment of GABAB receptor sites in the mammal central nervous system by means of ex vivo autoradiography or in vivo Positron Emission Tomography (PET).
摘要翻译：式（I）的羟基化或烷氧基化的N，P-芳烷基次膦酸衍生物，其中R1表示脂族，脂环族或芳族基团，R2和R5彼此独立地表示氢或脂族基团，R3表示氢或羟基，R4表示氢或R 3和R 4一起代表氧代，R 6表示氢或[3 H] - 或[11 C]标记的烷基，R 7表示氢，低级烷基，低级烷氧基，卤素，羧基，氨基甲酰基或氰基， X1和X2之一表示式> N-的基团，另一个表示式> P（= O）（OH） - 的基团，它们的盐是新的。其中R6表示氢的式（I）化合物可以容易地转化成相应的式（I）化合物，其中R 6表示[3 H] - 或[11 C] - 标记的烷基，其可接受的盐可用作通过离体放射自显影或体内正电子发射断层扫描（PET）定位和评估哺乳动物中枢神经系统中GABA B受体位点的工具。

53. 发明申请

WO1997010811A1 NANOPARTICLES IN PHOTODYNAMIC THERAPY 审中-公开
标题翻译：光化学治疗中的纳米颗粒
公开(公告)号：WO1997010811A1
公开(公告)日：1997-03-27
申请号：PCT/EP1996003956
申请日：1996-09-10
申请人： NOVARTIS AG , GURNY, Robert , ALLÉMANN, Eric, Olivier , LEROUX, Jean-Christophe , KRISTL, Julijana , DOELKER, Eric
发明人： NOVARTIS AG
IPC分类号： A61K09/51
CPC分类号： A61K41/0071 , A61K31/409
摘要： The present invention relates to a pharmaceutical composition in the form of an aqueous dispersion of nanoparticles comprising the zinc phthalocyanine complex and a polymer which is suitable for the formation of nanoparticles, to a process for the preparation of said pharmaceutical composition and to the therapeutic use thereof, e.g. in photodynamic therapy.
摘要翻译：本发明涉及一种纳米颗粒的水性分散体形式的药物组合物，其包含锌酞菁络合物和适于形成纳米颗粒的聚合物，涉及制备所述药物组合物的方法及其治疗用途，例如在光动力疗法中。

54. 发明申请

WO1998024919A1 GENETICALLY MODIFIED PSEUDOMONAS STRAINS WITH ENHANCED BIOCONTROL ACTIVITY 审中-公开
标题翻译：具有增强生物活性的遗传修饰的PSEUDOMONAS菌株
公开(公告)号：WO1998024919A1
公开(公告)日：1998-06-11
申请号：PCT/EP1997006815
申请日：1997-12-05
申请人： NOVARTIS AG
发明人： NOVARTIS AG , LIGON, James, Madison , HILL, Dwight, Steven , LAM, Stephen, Ting , GAFFNEY, Thomas, Deane , TORKEWITZ, Nancy, Reeves , STAFFORD, Jill, Michelle
IPC分类号： C12N15/78
CPC分类号： A01N63/00 , C07K14/21
摘要： Strains of Pseudomonas have been genetically engineered to have enhanced biocontrol properties. The strains of the invention are particularly effective against plant pathogenic fungi such as species of Rhizoctonia and Pythium, because the strains produce enhanced amounts of antifungal metabolites such as pyrrolnitrin that are active against these fungal pathogens. Both the genetically modified biocontrol strains and the antifungal metabolites can be used as active agents for biocontrol compositions.
摘要翻译：已将基因工程改造为具有增强的生物防治性质的假单胞菌菌株。本发明的菌株对于植物致病真菌如丝核菌属和腐霉属物种特别有效，因为菌株产生增加量的抗真菌代谢物，例如对这些真菌病原体具有活性的吡咯烷酮。遗传修饰的生物防治菌株和抗真菌代谢物均可用作生物防治组合物的活性剂。

55. 发明申请

WO1998023375A1 APPARATUS FOR CHANGING pH OF SOLUTIONS 审中-公开
标题翻译：改变溶液pH值的装置
公开(公告)号：WO1998023375A1
公开(公告)日：1998-06-04
申请号：PCT/EP1997006546
申请日：1997-11-24
申请人： NOVARTIS AG , TSAO, Fu-Pao
发明人： NOVARTIS AG
IPC分类号： B01J47/14
CPC分类号： A61F9/0008 , B01J39/07 , B01J41/07 , B01J47/016 , B01J47/15
摘要： The invention provides a method and an apparatus for altering the pH of a solution composition. The pH altering apparatus has a container body having a solution retaining chamber and an outlet, and a pH changing device having a modified ion exchange material selected from the group consisting of modified anion exchange materials and modified cation exchange materials, wherein the modified anion exchange materials contain a weak acid-forming counterion and the modified cation exchange materials contain a weak base-forming counterion.
摘要翻译：本发明提供了一种用于改变溶液组合物的pH的方法和装置。 pH改变装置具有具有溶液保留室和出口的容器主体，以及具有选自改性阴离子交换材料和改性阳离子交换材料的改性离子交换材料的pH改变装置，其中改性阴离子交换材料含有弱酸形成抗衡离子，改性阳离子交换材料含有弱碱形成抗衡离子。

56. 发明申请

WO1998017672A1 SUBSTITUTED AMINOALKANE PHOSPHONIC ACIDS 审中-公开
标题翻译：取代aminoalkanephosphonic酸
公开(公告)号：WO1998017672A1
公开(公告)日：1998-04-30
申请号：PCT/EP1997005843
申请日：1997-10-22
申请人： NOVARTIS AG , ACKLIN, Pierre , ALLGEIER, Hans , AUBERSON, Yves , OFNER, Silvio , VEENSTRA, Siem, Jacob
发明人： NOVARTIS AG
IPC分类号： C07F09/6509
CPC分类号： C07F9/650994
摘要： Compounds have the formula (I), in which R1 stands for hydroxy or an aliphatic, araliphatic or aromatic radical; X stands for a bivalent aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, araliphatic, heteroarylaliphatic or aromatic radical; R2 stands for hydrogen or an aliphatic or araliphatic radical; alk stands for lower alkylidene; and R3, R4 and R5 independently represent hydrogen, lower alkyl, halogen, trifluoromethyl, cyano or nitro. These compounds and their salts may be used for treating pathological conditions which respond to the blocking of exciter amino acid receptors, and for producing pharmaceutical compositions.
摘要翻译：式（I）其中R1是羟基或脂族，芳脂族或芳族基团的化合物; X为二价脂族，脂环族，脂环族 - 脂族，芳脂族，heteroarylaliphatic或芳族基团; R 2表示氢或脂族或芳脂族基团，alk是低级亚烷基; 和R 3，R 4和R 5独立地是氢，低级烷基，卤素，三氟甲基，氰基或硝基; 和它们的盐可被用于其中兴奋性氨基酸受体的阻断响应的病理状况的治疗，以及用于生产药物制剂。

57. 发明申请

WO1998016107A1 METHOD FOR THE PREVENTION OF THE REINFESTATION OF WARM-BLOODED ANIMALS BY ECTOPARASITES 审中-公开
标题翻译：防治热血病动物重组的方法
公开(公告)号：WO1998016107A1
公开(公告)日：1998-04-23
申请号：PCT/EP1997005639
申请日：1997-10-14
申请人： NOVARTIS AG , KARRER, Friedrich , GÖBEL, Thomas , HUMBERT-DROZ, Eliane
发明人： NOVARTIS AG
IPC分类号： A01N43/28
CPC分类号： A01N43/28 , A61K31/357
摘要： A method for the systemic control of blood-sucking parasites in warm-blooded animals or for the prevention of reinfestation, which comprises administering systemically to the warm-blooded animal a compound of formula (I), wherein R, R2, R3, R6, X and n are as defined in claim 1, in an amount that affects the growth of one of the early states of development of the parasite in such a manner that the parasite does not reach the adult stage or that the adult parasite is rendered sterile.
摘要翻译：一种用于系统地控制温血动物中吸血寄生虫或用于预防再感染的方法，其包括向所述温血动物全身施用式（I）化合物，其中R，R 2，R 3，R 6， X和n如权利要求1中所定义，其量以这样的方式影响寄生虫的早期发育状态的生长，使得寄生虫没有达到成年阶段或成年寄生虫无菌。

58. 发明申请

WO1998008810A1 ALKYLTHIO-, ALKYLSULPHINYL- AND ALKYLSULPHONYLCARBAMATES AS HERBICIDES 审中-公开
标题翻译：阿尔茨海默病，阿尔茨海默病和阿尔茨海默氏病作为除草剂
公开(公告)号：WO1998008810A1
公开(公告)日：1998-03-05
申请号：PCT/EP1997004626
申请日：1997-08-25
申请人： NOVARTIS AG , REMPFLER, Hermann , MÜHLEBACH, Michel , CEDERBAUM, Fredrik
发明人： NOVARTIS AG
IPC分类号： C07C323/43
CPC分类号： C07D333/48 , A01N47/12 , C07C309/66 , C07C317/28 , C07C323/43 , C07C323/60 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07D309/04 , C07D333/20
摘要： Compounds of formula (I) in which R is halogen, C1-C3haloalkyl, cyano, nitro or C1-C3haloalkoxy; Z is hydrogen, halogen or together with R, -O-CF2-O-; R1 is C1-C5alkyl or C3-C6cycloalkyl; R2 and R3 independently of one another are hydrogen, C1-C4alkyl or C3-C6cycloalkyl; R4 is C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl or C5- or C6-cycloalkenyl, or is C1-C4alkyl, C2-C6alkenyl, C2-C6alkynyl or C3-C6cycloalkyl, each of which is substituted by halogen, cyano, C1-C4alkyl-CO, phenyl-CO, COOR5, C1-C4alkoxy, C1-C4haloalkoxy, oxiranyl, dioxolanyl, tetrahydrofuranyl, tetrahydropyranyl, C3-C6cycloalkyl, halo-C3-C6-cycloalkyl, phenyl or phenoxy, it being possible for the phenyl group, in turn, to be substituted by halogen, C1-C3alkyl, C1-C4alkoxy, cyano or C1-C3haloalkyl, or is phenyl or phenyl which is substituted by halogen, C1-C3alkyl, C1-C4alkoxy, cyano or C1-C3haloalkyl; or R4 together with one of the R2 groups forms a C2-C6alkylene bridge; R5 is C1-C5alkyl or C3-C6cycloalkyl; n is the number 1, 2, or 3 and m is thenumber 0, 1 or 2; and the diastereomers and enantiomers of these compounds are suitable as herbicides.
摘要翻译：其中R是卤素，C 1 -C 3卤代烷基，氰基，硝基或C 1 -C 3卤代烷氧基的式（I）化合物; Z是氢，卤素或与R，-O-CF2-O-一起; R1是C1-C5烷基或C3-C6环烷基; R2和R3彼此独立地是氢，C1-C4烷基或C3-C6环烷基; R4是C1-C6烷基，C2-C6链烯基，C2-C6炔基，C3-C6环烷基或C5-或C6-环烯基，或是C1-C4烷基，C2-C6链烯基，C2-C6炔基或C3-C6环烷基，其各自被卤素，氰基，C 1 -C 4烷基-CO，苯基-CO，COOR 5，C 1 -C 4烷氧基，C 1 -C 4卤代烷氧基，环氧乙烷基，二氧戊环基，四氢呋喃基，四氢吡喃基，C 3 -C 6环烷基，卤代C 3 -C 6环烷基，苯基或苯氧基苯基被卤素，C 1 -C 3烷基，C 1 -C 4烷氧基，氰基或C 1 -C 3卤代烷基取代，或被苯基或被卤素，C 1 -C 3烷基，C 1 -C 4烷氧基，氰基或C 1 -C 4烷氧基取代的苯基 -C3haloalkyl; 或R4与一个R2基团形成C2-C6亚烷基桥; R5是C1-C5烷基或C3-C6环烷基; n为1,2或3，m为0,1或2，并且这些化合物的非对映异构体和对映异构体适用作除草剂。

59. 发明申请

WO1998007694A1 ACYLAMINOALKENYLENE-AMIDE DERIVATIVES AS NK1 AND NK2 ANTAGONISTS 审中-公开
标题翻译：作为NK1和NK2拮抗剂的亚氨基亚氨基酰胺衍生物
公开(公告)号：WO1998007694A1
公开(公告)日：1998-02-26
申请号：PCT/EP1997004436
申请日：1997-08-13
申请人： NOVARTIS AG , GERSPACHER, Marc , VON SPRECHER, Andreas , MAH, Robert , ROGGO, Silvio , STUTZ, Stefan
发明人： NOVARTIS AG
IPC分类号： C07D209/20
CPC分类号： C07D403/12 , C07C237/22 , C07D209/20 , C07D209/24 , C07D223/12
摘要： Compounds of formula (I) wherein R is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen, lower alkyl, trifluoromethyl, hydroxy and lower alkoxy; R1 is hydrogen or lower alkyl, R2 is hydrogen, lower alkyl or phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen, lower alkyl, trifluoromethyl, hydroxy and lower alkoxy, R3 is phenyl that is unsubstituted or is substituted by 1, 2 or 3 substituents selected from the group halogen, lower alkyl, trifluoromethyl, hydroxy and lower alkoxy; or is naphthyl, 1H-indol-3-yl or 1-lower alkyl-indol-3-yl, R4' and R4'' are each independently of the other hydrogen or lower alkyl, at least one of the radicals R4' and R4'' being hydrogen, and R5 is C3-C8cycloalkyl, D-azacycloheptan-2-on-3-yl or L-azacycloheptan-2-on-3-yl; or a salt thereof, have valuable pharmaceutical properties and are effective especially as NK1 and NK2 antagonists.
摘要翻译：式（I）的化合物，其中R是未被取代或被1,2或3个选自卤素，低级烷基，三氟甲基，羟基和低级烷氧基的取代基取代的苯基; R 1是氢或低级烷基，R 2是氢，未被取代的或被1,2或3个选自卤素，低级烷基，三氟甲基，羟基和低级烷氧基的取代基取代的低级烷基或苯基，R 3是未取代的或被1,2或3个选自卤素，低级烷基，三氟甲基，羟基和低级烷氧基的取代基取代; 或是萘基，1H-吲哚-3-基或1-低级烷基 - 吲哚-3-基，R 4'和R 4“各自独立地为另一个氢或低级烷基，基团R 4'和R 4中的至少一个 “为氢，R5为C3-C8环烷基，D-氮杂环庚烷-2-基-3-基或L-氮杂环庚烷-2-基-3-基; 或其盐具有有价值的药物性质，特别是作为NK1和NK2拮抗剂是有效的。

60. 发明申请

WO1998003644A1 TRANSGENIC ANIMAL MODEL FOR ALZHEIMER DISEASE 审中-公开
标题翻译：阿尔茨海默病的转基因动物模型
公开(公告)号：WO1998003644A1
公开(公告)日：1998-01-29
申请号：PCT/EP1997003991
申请日：1997-07-23
申请人： NOVARTIS AG , SOMMER, Bernd , STAUFENBIEL, Matthias
发明人： NOVARTIS AG
IPC分类号： C12N15/00
CPC分类号： C12N15/8509 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/0312 , C07K14/4711 , C12N2830/008
摘要： The invention provides transgenic non-human animals which exhibit both APP and tau-linked features, e.g. histological features, of AD pathology, and preferably also behavioural changes characteristic of AD. Suitably the transgenic non-human animals express a human APP comprising the Swedish mutation or the Swedish mutation in combination with one or more additional mutations, in particular the London mutation. It appears that the level at which the transgene is expressed in the transgenic animal, e.g. the level of transgene mRNA, is an important factor for obtaining AD pathology in the animal. Transgenic mice expressing said mutated human APP under control of Thy-1 promoter element have been found to develop a pathological phenotype which goes beyond that previously described by Games et al. [Nature 373, 523-527, (1995)], by combining APP and tau-linked features of the AD pathology. Moreover, the mice have been found to present behavioural changes characteristic of AD, which has also never been reported before with transgenic animals.
摘要翻译：本发明提供了表达APP和tau连锁特征的转基因非人动物，例如。 AD病理学的组织学特征，优选AD的行为变化特征。适当地，转基因非人动物表达包含瑞典突变或瑞典突变的人APP与一个或多个另外的突变，特别是伦敦突变的组合。似乎转基因在转基因动物中表达的水平，例如转基因mRNA的水平是动物获得AD病理学的重要因素。已经发现在Thy-1启动子元件的控制下表达所述突变的人APP的转基因小鼠的病理表现超出了Games等人先前描述的 [Nature 373,523-527，（1995）]，通过结合AD病理学的APP和tau连锁特征。此外，已经发现小鼠存在AD转基因特征的行为变化，以前从未报道过转基因动物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式